Have a feature idea you'd love to see implemented?
Let us know!
CCCC C4 Therapeutics Inc
Price (delayed)
$4.01
Market cap
$283.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.7
Enterprise value
$287.06M
C4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment
Highlights
CCCC's gross profit has surged by 65% year-on-year and by 15% since the previous quarter
The company's revenue has surged by 65% YoY and by 15% QoQ
The quick ratio is up by 25% since the previous quarter but it has declined by 15% year-on-year
Key stats
What are the main financial stats of CCCC
Market
Valuations
Earnings
Shares outstanding
70.59M
Market cap
$283.06M
Enterprise value
$287.06M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.15
Price to sales (P/S)
8.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.53
Revenue
$33.67M
EBIT
-$105.22M
EBITDA
-$97.1M
Free cash flow
-$71.58M
Per share
Balance sheet
Liquidity
EPS
-$1.7
Free cash flow per share
-$1.03
Book value per share
$3.5
Revenue per share
$0.48
TBVPS
$5.4
Total assets
$376.06M
Total liabilities
$133.4M
Debt
$67.1M
Equity
$242.66M
Working capital
$229.94M
Debt to equity
0.28
Current ratio
6.31
Quick ratio
6.22
Net debt/EBITDA
-0.04
Margins
Efficiency
Dividend
EBITDA margin
-288.4%
Gross margin
100%
Net margin
-313.3%
Operating margin
-354.4%
Return on assets
-27.5%
Return on equity
-42.4%
Return on invested capital
-33.7%
Return on capital employed
-31.6%
Return on sales
-312.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CCCC stock price
How has the C4 Therapeutics stock price performed over time
Intraday
-0.99%
1 week
-15.04%
1 month
-35.84%
1 year
170.95%
YTD
-29.03%
QTD
-29.65%
Financial performance
How have C4 Therapeutics's revenue and profit performed over time
Revenue
$33.67M
Gross profit
$33.67M
Operating income
-$119.33M
Net income
-$105.5M
Gross margin
100%
Net margin
-313.3%
CCCC's gross profit has surged by 65% year-on-year and by 15% since the previous quarter
The company's revenue has surged by 65% YoY and by 15% QoQ
The company's net margin has surged by 53% YoY and by 15% QoQ
The operating margin has grown by 48% YoY and by 12% from the previous quarter
Growth
What is C4 Therapeutics's growth rate over time
Valuation
What is C4 Therapeutics stock price valuation
P/E
N/A
P/B
1.15
P/S
8.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.53
The EPS has increased by 38% year-on-year and by 11% since the previous quarter
The price to book (P/B) is 52% lower than the 5-year quarterly average of 2.4 and 28% lower than the last 4 quarters average of 1.6
C4 Therapeutics's equity has increased by 12% YoY
The company's revenue has surged by 65% YoY and by 15% QoQ
CCCC's price to sales (P/S) is 61% less than its 5-year quarterly average of 21.1 and 48% less than its last 4 quarters average of 16.0
Efficiency
How efficient is C4 Therapeutics business performance
The return on sales has surged by 52% year-on-year and by 14% since the previous quarter
The company's return on assets rose by 22% YoY and by 5% QoQ
C4 Therapeutics's ROE has increased by 21% YoY and by 4.9% from the previous quarter
C4 Therapeutics's return on invested capital has increased by 4% YoY and by 3.2% QoQ
Dividends
What is CCCC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CCCC.
Financial health
How did C4 Therapeutics financials performed over time
C4 Therapeutics's total assets is 182% more than its total liabilities
The quick ratio is up by 25% since the previous quarter but it has declined by 15% year-on-year
The current ratio is up by 24% QoQ but it is down by 15% YoY
The company's debt is 72% lower than its equity
CCCC's debt to equity is down by 15% year-on-year
C4 Therapeutics's equity has increased by 12% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.